The HPTN showcased key data and valuable insights during the AIDS 2024 conference, including symposia and posters on the use and implementation of long-acting cabotegravir for pre-exposure prophylaxis (PrEP), the effectiveness of PrEP in different populations, and notable innovative strategies used in HIV prevention.

Follow the HPTN on social media (@HIVptn) for highlights.

HPTN at AIDS 2024:

Global Village

The HPTN collaborated with the HIV Vaccine Trials Network to host a Networking Zone in the Global Village:

Help End HIV: Clinical Trials for HIV Prevention
July 22-26, 10:00 a.m. - 4:00 p.m. CEST
Booth #: HT06

Presentations

• Oral Abstract Session
  Advanced HIV Disease: Hiding in Plain Sight
  July 23, 3:00 p.m. - 4:00 p.m. CEST
  Room 14b/Channel 3
  • Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study [Slides] Raphael Landovitz

• Symposium
  SY25 Use of long-acting injectable cabotegravir in pregnant and lactating people
  July 25, 10:30 a.m. - 11:30 a.m. CEST
  Room 13a/Channel 7
  • Safety of injectable cabotegravir in pregnancy: Results from HPTN 084 | Sinead Delany-Moretlwe
  • Pharmacokinetics and dosing requirements for injectable cabotegravir during pregnancy: Results from HPTN 084 | Mark Marzinke

Posters 

• Association between substance use and PrEP adherence among AGYW enrolled in an HIV prevention study (HPTN 082) in Southern Africa 

• Pre-Exposure Prophylaxis product choice of participants in HPTN 083 

• A community-academic partnership to empower Black MSM for economic development, advocacy, and HIV prevention research: HPTN 096 

• Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study 

• What factors influence whether stigmatizing attitudes change over time? An analysis of HIV stigma attitudes and perceptions among community members participating in the HPTN 071 (PopART) trial 

• HPTN 094: Engaging Key Community Stakeholders in Preparation for Mobile Clinics Providing Integrated Health Services (Medication for Opioid Use Disorder and HIV Treatment/Prevention Services) for People Who Inject Drugs (PWID) 

• Understanding Parental Motivations and Decision-Making for Adolescent Girls’ Participation in the Long-Acting Cabotegravir (CAB-LA) Trial – Insights from HPTN 084-1 

• First-in-human evaluation of the safety, pharmacokinetics, and neutralization activity of PGDM1400-LS, a V2 glycan-specific HIV-1 broadly neutralizing antibody, infused intravenously or subcutaneously in people without HIV-1 (HVTN140/HPTN101 Part A) 

• A first-in-human phase 1 trial of PGT121.414.LS administered alone and in combination with VRC07-523LS: safety, tolerability, pharmacokinetics, and neutralization activity (HVTN 136/HPTN 092) 

• Enhancing Inclusivity: Examining the Global Impact of Cultural Competency on Clinical Trial Recruitment in HPTN – 10 Year Update 

• “Everyone should have access to it”: perspectives on PrEP product choice and implementation from MSM and TGW in an injectable PrEP trial

For a complete list of activities, browse the conference program.